InnoCare’s Orelabrutinib Receives the NMPA’s Approval for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma
- The NMPA has approved orelabrutinib (BTK inhibitor) in China for r/r MZL. Orelabrutinib showed a high response with durable disease remission in Chinese patients thus supporting the use of orelabrutinib as an effective & tolerable oral treatment option
- The therapy received BTD from the US FDA for r/r MCL & received conditional approval from the NMPA for r/r CLL/SLL and the treatment of r/r MCL. Orelabrutinib’s sNDA was under the NMPA’s priority review for the treatment of patients with r/r MZL
- Orelabrutinib is currently undergoing clinical trials in the US & China as a monotx. or in combination therapies, such as the 1L treatment of DLBCL with the MCD subtype
Ref: BusinessWire | Image: InnoCare
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.